Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Cash from Financing Activities (2016 - 2025)

Tandem Diabetes Care's Cash from Financing Activities history spans 13 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 13.12% year-over-year to $2.6 million; the TTM value through Dec 2025 reached -$43.4 million, down 618.31%, while the annual FY2025 figure was -$43.4 million, 618.31% down from the prior year.
  • Cash from Financing Activities reached $2.6 million in Q4 2025 per TNDM's latest filing, up from -$1.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $18.8 million in Q3 2021 to a low of -$39.7 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $1.9 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: soared 2611.28% in 2024, then tumbled 1222.88% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $15.9 million in 2021, then tumbled by 61.6% to $6.1 million in 2022, then plummeted by 57.1% to $2.6 million in 2023, then fell by 12.04% to $2.3 million in 2024, then increased by 13.12% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Cash from Financing Activities are $2.6 million (Q4 2025), -$1.6 million (Q3 2025), and -$39.7 million (Q2 2025).